The environment in which the encounter of antigen with the immune system occurs determines whether tolerance, infectious immunity, or autoimmunity results. Geographical areas with low supplies of vitamin D (for example Scandinavia) correlate with regions with high incidences of multiple sclerosis, arthritis, and diabetes. The active form of vitamin D has been shown to suppress the development of autoimmunity in experimental animal models. Furthermore, vitamin D deficiency increases the severity of at least experimental autoimmune encephalomyelitis (mouse multiple sclerosis). Targets for vitamin D in the immune system have been identified, and the mechanisms of vitamin D-mediated immunoregulation are beginning to be understood. This review discusses the possibility that vitamin D status is an environmental factor, which by shaping the immune system affects the prevalence rate for autoimmune diseases such as multiple sclerosis, arthritis, and juvenile diabetes.
Get full access to this article
View all access options for this article.
References
1.
HayesCE, CantornaMT, DeLucaHF. Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med216:21–27, 1997.
2.
GoldbergP.Multiple sclerosis: Vitamin D and calcium as environmental determinants of prevalence: Sunlight, dietary factors, and epidemiology. Int J Environ Studies6:19–27, 1974.
3.
KeenH, EkoeJM. The geography of diabetes mellitus. Br Med J40:359–365, 1984.
4.
LawrenceJS, BehrendT, BennettPH, BremnerJM, BurchTA, GoftonJ, O'BrienW, RobinsonH.Geographical studies of rheumatoid arthritis. Ann Rheum Dis25:425–432, 1966.
5.
StrydRP, GilbertsonTJ, BrundenMN. A seasonal variation study of 25–hydroxyvitamin D3 serum levels in normal humans. J Clin Endocrinol Metab48:771–775, 1979.
6.
CosmanF, NievesJ, KomarL, FerrerG, HerbertJ, FormicaC, ShenV, LindsayR.Fracture history and bone loss in patients with MS. Neurology51:1161–1165, 1998.
7.
NievesJ, CosmanF, HerbertJ, ShenV, LindsayR.High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology44:1687–1692, 1994.
8.
Ai-QadrehA, VoskakiI, KassiouC, AthanasopoulouH, SarafidouE, BartsocasCS. Treatment of osteopenia in children with insulin-dependent diabetes mellitus: The effect of 1α-hydroxyvitamin D3. Eur J Pediatr155:15–17, 1996.
9.
HillmanL, CassidyJT, JohnsonL, LeeD, AllenSH. Vitamin D metabolism and bone mineralization in children with juvenile rheumatoid arthritis. J Pediatr124:910–916, 1994.
10.
WraithDC, McDevittHO, SteinmanL, Acha-OrbaeH.T-cell recognition as the target for immune intervention in autoimmune disease. Cell57:709–715. 1989.
11.
HaskinsK, McDuffieM.Acceleration of diabetes in young NOD mice with CD4+ islet-specific T cell clone. Science249:1433–1436, 1990.
12.
LemireJM, WeigleWO. Passive transfer of experimental allergic encephalomyelitis by myelin basic protein-specific L3T4+ T cell clones possessing several functions. J Immunol137:3169–3174, 1986.
13.
KoikeT, ItohY, TatsukoI, ItoI, TakabayashiK, MaruyamaN, TomiokaH, YoshidaS.Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes36:539–541, 1987.
14.
WaldorMK, SriramS, HardyR, HerzenbergLA, HerzenbergLA, LanierL, LimM, SteinmanL.Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science227:415–417, 1985.
15.
RangesGE, SriramS, CooperSM. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med162:1105–1110, 1985.
16.
BoltonC.Recent advances in the pharmacological control of experimental allergic encephalomyelitis (EAE) and the implications for multiple sclerosis treatment. Mult Scler1:143–149, 1995.
17.
HoldaJH, SwanborgRH. Autoimmune effector cells II. Transfer of experimental allergic encephalomyelitis with a subset of T lymphocytes. Eur J Immunol12:342–344, 1982.
18.
LiblauRS, SingerSM, McDevittHO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today16:34–38, 1995.
19.
CorrealeJ, GilmoreW, McMillanM, LiS, McCarthyK, LeT, WeinerLP. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T-cell clones during the course of multiple sclerosis. J Immunol154:2959–2968, 1995.
20.
RackeMK, BonomoA, ScottDE, CannellaB, LevineA, RaineCS, ShevachES, RockenM.Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med180:1961–1966, 1994.
21.
CoffmanRL, VarkilaK, ScottP, ChatelainR.Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo.Immunol Rev123:189–207, 1991.
22.
BhallaAK, AmentoEP, ClemensTL, HolickMF, KraneSM. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: Presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab570:1308–1310, 1983.
23.
ProvvediniDM, TsoukasCD, DeftosLJ, ManolagasSC. 1,25–dihydroxyvitamin D3 receptors in human leukocytes. Science221:1181–1183, 1983.
24.
CantornaMT, HayesCE, DeLucaHF. 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis. Proc Natl Acad Sci U S A93:7861–7864, 1996.
25.
CantornaMT, HayesCE, DeLucaHF. 1,25-dihydroxyvitamin D3 prevents and ameliorates symptoms in two experimental models of human arthritis. J Nutr128:68–72, 1998.
LemireJM. Immunomodulatory role of 1,25-dihydroxyvitamin D3. J Cell Biochem49:26–31, 1992.
28.
LemireJM, AdamsJS. 1,25-dihydroxy vitamin D3 inhibits the passive transfer of cellular immunity by a myelin basic protein-specific T-cell clone. J Bone Miner Res7:171–177, 1992.
29.
LemireJM, ArcherDC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest87:1103–1107, 1991.
30.
DeLucaHF. The vitamin D story: A collaborative effort of basic science and clinical medicine. FASEB J2:224–236, 1988.
31.
LemireJM, ArcherDC, BeckL, SpiegelbergHL. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: Preferential inhibition of Th1 functions. J Nutr125:1704S-1708S, 1995.
32.
D'AmbrosioD, CippitelliM, CoccioloMG, MazzeoD, Di LuciaP, LangR, SinigagliaF, Panina-BordignonP.Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3: Involvement of NF-κB downregulation in transcriptional repression of the p40 gene. J Clin Invest101:252–262, 1998.
33.
CantornaMT, WoodwardB, HayesCE, DeLucaHF. 1,25-dihydroxyvitamin D3 is a positive regulator for the two antiencephalitogenic cytokines TGF-β1 and IL-4. J Immunol160:5314–5319, 1998.
34.
MurphyKM. OuyangW, SzaboSJ, JacobsonNG, GulerML, GorhamJD, GublerU, MurphyTL. T-helper differentiation proceeds through Stat1–defendant, Stat4–dependent, and Stat4–independent phases. Curr Top Microbiol Immunol238:13–26, 1999.
35.
KaplanMH, GrusbyMJ. Regulation of T-helper cell differentiation by STAT molecules. J Leukoc Biol64:2–5, 1998.
36.
OuyangW, RanganathSH, WeindelK, BhattacharyaD, MurphyTL, ShaWC, MurphyKM. Inhibition of Th1 development mediated by GATA-3 through an IL-4–independent mechanism. Immunity9:745–755, 1998.
37.
AlroyI, TowersTL, FreedmanLP. Transcriptional repression of the interleukin-2 gene by vitamin D3: Direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol15:5789–5799, 1995.
38.
TakeuchiA, ReddyGS, KobayashiT, OkanoT, ParkJ, SharmaS.Nuclear factor of activated T cells (NFAT) as a molecular target for 1α, 25-dihydroxyvitamin D3-mediated effects. J Immunol160:209–218, 1998.
39.
RossTK, DarwishHM. DeLucaHF. Molecular biology of vitamin D action. In: LitwackG, Ed. Vitamins and Hormones. San Diego: Academic Press, Vol 49:pp281–326, 1994.
